Published in Clin Cancer Res on November 15, 2006
Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev (2008) 4.80
Targeting of drugs and nanoparticles to tumors. J Cell Biol (2010) 4.07
Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev (2008) 3.34
Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials (2007) 3.12
Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J Control Release (2007) 2.74
Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science (2012) 2.73
Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev (2010) 2.44
Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics (2012) 2.35
Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine (2008) 2.20
Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small (2009) 2.16
Magnetic Iron Oxide Nanoworms for Tumor Targeting and Imaging. Adv Mater (2008) 2.01
In vivo tumor cell targeting with "click" nanoparticles. Bioconjug Chem (2008) 2.01
Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small (2009) 1.93
EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res (2010) 1.79
Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery. Angew Chem Int Ed Engl (2008) 1.71
Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev (2010) 1.63
Cancer theranostics: the rise of targeted magnetic nanoparticles. Trends Biotechnol (2011) 1.60
Chlorotoxin labeled magnetic nanovectors for targeted gene delivery to glioma. ACS Nano (2010) 1.52
Peptide-based probes for targeted molecular imaging. Biochemistry (2010) 1.43
Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv Mater (2012) 1.41
Nanoparticles for applications in cellular imaging. Nanoscale Res Lett (2007) 1.34
Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics. Theranostics (2012) 1.30
High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.30
Development and applications of photo-triggered theranostic agents. Adv Drug Deliv Rev (2010) 1.29
Vessel microport technique for applications in cerebrovascular research. J Neurosci Res (2009) 1.28
Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles. Nanomedicine (Lond) (2008) 1.22
Inorganic nanoparticle-based contrast agents for molecular imaging. Trends Mol Med (2010) 1.21
Nanoparticle PEBBLE sensors in live cells and in vivo. Annu Rev Anal Chem (Palo Alto Calif) (2009) 1.18
Development of Receptor Targeted Magnetic Iron Oxide Nanoparticles for Efficient Drug Delivery and Tumor Imaging. J Biomed Nanotechnol (2008) 1.17
Self-assembly synthesis, tumor cell targeting, and photothermal capabilities of antibody-coated indocyanine green nanocapsules. J Am Chem Soc (2010) 1.13
F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo. Cancer Res (2010) 1.09
Encapsulation of methylene blue in polyacrylamide nanoparticle platforms protects its photodynamic effectiveness. Biochem Biophys Res Commun (2008) 1.07
Multifunctional nanoparticles for brain tumor imaging and therapy. Adv Drug Deliv Rev (2013) 1.07
A surface-charge study on cellular-uptake behavior of F3-peptide-conjugated iron oxide nanoparticles. Small (2009) 1.07
Photodynamic nanomedicine in the treatment of solid tumors: perspectives and challenges. J Control Release (2013) 1.05
Small solutions for big problems: the application of nanoparticles to brain tumor diagnosis and therapy. Clin Pharmacol Ther (2009) 1.05
Magnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapy. Expert Rev Clin Pharmacol (2012) 1.03
Tissue distribution and pharmacokinetics of stable polyacrylamide nanoparticles following intravenous injection in the rat. Toxicol Appl Pharmacol (2010) 1.02
In vitro characterization of a targeted, dye-loaded nanodevice for intraoperative tumor delineation. Neurosurgery (2009) 1.00
Methylene blue covalently loaded polyacrylamide nanoparticles for enhanced tumor-targeted photodynamic therapy. Photochem Photobiol Sci (2011) 1.00
Near infrared luminescent oxygen nanosensors with nanoparticle matrix tailored sensitivity. Anal Chem (2010) 0.99
Drug delivery to brain tumors. Curr Neurol Neurosci Rep (2008) 0.98
A molecularly targeted theranostic probe for ovarian cancer. Mol Cancer Ther (2010) 0.98
Shedding light on nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2012) 0.97
Multifunctional Peptide-conjugated hybrid silica nanoparticles for photodynamic therapy and MRI. Theranostics (2012) 0.96
Novel methods to incorporate photosensitizers into nanocarriers for cancer treatment by photodynamic therapy. Lasers Surg Med (2011) 0.95
Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: what should be the policy? Neuroimage (2010) 0.95
The brain tumor window model: a combined cranial window and implanted glioma model for evaluating intraoperative contrast agents. Neurosurgery (2010) 0.95
Targeted imaging and therapy of brain cancer using theranostic nanoparticles. Mol Pharm (2010) 0.94
Vascular-targeted photothermal therapy of an orthotopic murine glioma model. Nanomedicine (Lond) (2012) 0.93
Nanoparticles for imaging and treating brain cancer. Nanomedicine (Lond) (2013) 0.90
The magnetophoretic mobility and superparamagnetism of core-shell iron oxide nanoparticles with dual targeting and imaging functionality. Biomaterials (2010) 0.89
Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking. Front Chem (2014) 0.89
Can nanotechnology potentiate photodynamic therapy? Nanotechnol Rev (2012) 0.89
Magnetic nanoparticles for tumor imaging and therapy: a so-called theranostic system. Pharm Res (2013) 0.88
Nanoparticles for Improving Cancer Diagnosis. Mater Sci Eng R Rep (2013) 0.87
Serial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101. Clin Cancer Res (2013) 0.85
Synthesis and investigation of a radioiodinated F3 peptide analog as a SPECT tumor imaging radioligand. PLoS One (2011) 0.84
Multifunctional hierarchically assembled nanostructures as complex stage-wise dual-delivery systems for coincidental yet differential trafficking of siRNA and paclitaxel. Nano Lett (2013) 0.83
Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases. Nanomedicine (2015) 0.82
Shining light on nanotechnology to help repair and regeneration. Biotechnol Adv (2012) 0.82
Photothermal therapy of cancer cells mediated by blue hydrogel nanoparticles. Nanomedicine (Lond) (2013) 0.82
Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle. Cancer Res (2015) 0.82
Polyacrylamide-based biocompatible Nanoplatform enhances the tumor uptake, PET/fluorescence imaging and anticancer activity of a chlorophyll analog. Theranostics (2014) 0.81
Modulation of hydrogel nanoparticle intracellular trafficking by multivalent surface engineering with tumor targeting peptide. Nanoscale (2013) 0.81
Highly stable polymer coated nano-clustered silver plates: a multimodal optical contrast agent for biomedical imaging. Nanotechnology (2014) 0.79
A technical description of the brain tumor window model: an in vivo model for the evaluation of intraoperative contrast agents. Acta Neurochir Suppl (2011) 0.79
Eradication of bacteria in suspension and biofilms using methylene blue-loaded dynamic nanoplatforms. Antimicrob Agents Chemother (2009) 0.79
111In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin. EJNMMI Res (2012) 0.78
"Clickable" polymer nanoparticles: a modular scaffold for surface functionalization. Chem Commun (Camb) (2010) 0.78
Computational Modeling of Tumor Response to Drug Release from Vasculature-Bound Nanoparticles. PLoS One (2015) 0.78
Nanotechnology applications for glioblastoma. Neurosurg Clin N Am (2012) 0.78
Inductive heating kills cells that contribute to plaque: a proof-of-concept. PeerJ (2015) 0.77
Gold nanoparticles as multimodality imaging agents for brain gliomas. J Nanobiotechnology (2015) 0.77
Nanomedicine: a primer for surgeons. Pediatr Surg Int (2012) 0.76
Targeted photodynamic therapy in head and neck squamous cell carcinoma: heading into the future. Lasers Med Sci (2015) 0.76
Mutagenic Effects of Iron Oxide Nanoparticles on Biological Cells. Int J Mol Sci (2015) 0.76
Crossing the barrier: treatment of brain tumors using nanochain particles. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.76
CD44v6-Peptide Functionalized Nanoparticles Selectively Bind to Metastatic Cancer Cells. Adv Sci (Weinh) (2016) 0.75
Synthesis and evaluation of an (18) F-labeled derivative of F3 for targeting surface-expressed nucleolin in cancer and tumor endothelial cells. J Labelled Comp Radiopharm (2016) 0.75
Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.75
Treatment of near-infrared photodynamic therapy using a liposomally formulated indocyanine green derivative for squamous cell carcinoma. PLoS One (2015) 0.75
Radiosensitivity enhancement of radioresistant glioblastoma by epidermal growth factor receptor antibody-conjugated iron-oxide nanoparticles. J Neurooncol (2015) 0.75
Photodynamic therapy of tumors with pyropheophorbide-a-loaded polyethylene glycol-poly(lactic-co-glycolic acid) nanoparticles. Int J Nanomedicine (2016) 0.75
Specific biomarkers of receptors, pathways of inhibition and targeted therapies: pre-clinical developments. Br J Radiol (2011) 0.75
Photonanomedicine: a convergence of photodynamic therapy and nanotechnology. Nanoscale (2016) 0.75
Dual-functional lipid-like nanoparticles for delivery of mRNA and MRI contrast agents. Nanoscale (2017) 0.75
In vitro characterization and in vivo ultrasound molecular imaging of nucleolin-targeted microbubbles. Biomaterials (2016) 0.75
One-pot synthesis of nanochain particles for targeting brain tumors. Nanoscale (2017) 0.75
Formulation of long-wavelength indocyanine green nanocarriers. J Biomed Opt (2017) 0.75
Ultrasmall AGuIX theranostic nanoparticles for vascular-targeted interstitial photodynamic therapy of glioblastoma. Int J Nanomedicine (2017) 0.75
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Safe handling of nanotechnology. Nature (2006) 7.25
Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia (2011) 5.53
Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A (2005) 4.63
CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A (2007) 3.85
Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A (2005) 3.15
Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials (2007) 3.12
Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med (2012) 2.95
Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol (2010) 2.90
Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol (2008) 2.84
Meta-analysis of functional neuroimaging studies of emotion perception and experience in schizophrenia. Biol Psychiatry (2011) 2.76
It's not just about anatomy: in vivo bioluminescence imaging as an eyepiece into biology. J Magn Reson Imaging (2002) 2.58
Towards hyperpolarized (13)C-succinate imaging of brain cancer. J Magn Reson (2007) 2.57
Targeted gold nanoparticles enable molecular CT imaging of cancer. Nano Lett (2008) 2.55
Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol (2007) 2.39
Biological stress response terminology: Integrating the concepts of adaptive response and preconditioning stress within a hormetic dose-response framework. Toxicol Appl Pharmacol (2007) 2.37
The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med (2009) 2.32
The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia (2006) 2.30
Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther (2003) 2.28
PASADENA hyperpolarization of succinic acid for MRI and NMR spectroscopy. J Am Chem Soc (2008) 2.27
Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-Gluco-RGD autoradiography. J Nucl Med (2008) 2.22
A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol (2009) 2.10
Evaluation of lung MDCT nodule annotation across radiologists and methods. Acad Radiol (2006) 2.00
Real-time measurements of dissolved oxygen inside live cells by organically modified silicate fluorescent nanosensors. Anal Chem (2004) 1.97
Affinity peptide for targeted detection of dysplasia in Barrett's esophagus. Gastroenterology (2010) 1.93
Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci U S A (2002) 1.93
Indocyanine-green-embedded PEBBLEs as a contrast agent for photoacoustic imaging. J Biomed Opt (2007) 1.83
Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging (2010) 1.82
Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys (2005) 1.79
In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice. Cancer Biol Ther (2003) 1.77
Identification of pathogen and host-response markers correlated with periodontal disease. J Periodontol (2009) 1.72
Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J Neurosci (2003) 1.72
The new toxicology of sophisticated materials: nanotoxicology and beyond. Toxicol Sci (2010) 1.71
Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg (2011) 1.68
Molecular imaging of Akt kinase activity. Nat Med (2007) 1.68
Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev (2006) 1.66
Radon, smoking, and lung cancer: the need to refocus radon control policy. Am J Public Health (2013) 1.65
A methodology for registration of a histological slide and in vivo MRI volume based on optimizing mutual information. Mol Imaging (2006) 1.63
T2-weighted MR imaging in the assessment of cirrhotic liver. Radiology (2004) 1.61
Multi-system repeatability and reproducibility of apparent diffusion coefficient measurement using an ice-water phantom. J Magn Reson Imaging (2012) 1.57
Photodynamic characterization and in vitro application of methylene blue-containing nanoparticle platforms. Photochem Photobiol (2005) 1.56
PASADENA hyperpolarization of 13C biomolecules: equipment design and installation. MAGMA (2008) 1.56
Hyperpolarized water as an MR imaging contrast agent: feasibility of in vivo imaging in a rat model. Radiology (2012) 1.54
Clinical proton MR spectroscopy in central nervous system disorders. Radiology (2014) 1.53
Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging (2002) 1.53
A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia (2007) 1.50
Diffusion coefficient measurement using a temperature-controlled fluid for quality control in multicenter studies. J Magn Reson Imaging (2011) 1.50
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res (2007) 1.48
Cell-specific nanoplatform-enabled photodynamic therapy for cardiac cells. Heart Rhythm (2012) 1.48
Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proc Natl Acad Sci U S A (2005) 1.44